THE Therapeutic Goods Administration is monitoring the safety of products that contain Camellia sinensis (green tea extracts) in light of "rare cases of harm to the liver".
Camellia sinensis is a herbal ingredient permitted for use in low risk medicines in Australia, included in approximately 267 listed medicines in the ARTG.
The majority contain it as a concentrated extract, with these products often used to assist with weight management and as a source of antioxidants.
Incidence of liver toxicity is "rare and unpredictable" and the TGA considers a recall is not warranted.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Jun 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Jun 18
